# Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes

Study · id `cardio:ct-nct06825182` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06825182](<https://clinicaltrials.gov/study/NCT06825182>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06825182

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT06825182. Allocation not applicable; no masking; primary purpose treatment. Start 2024-11-07 (actual); primary completion 2025-08-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT06825182, source copy `cardio:ctgov-nct06825182-2025-02-13`, retrieved 2026-10-26)
- Started: 2024-11-07 (actual) (ClinicalTrials.gov record NCT06825182, source copy `cardio:ctgov-nct06825182-2025-02-13`, retrieved 2026-10-26)
- Primary completion: 2025-08-01 (anticipated) (ClinicalTrials.gov record NCT06825182, source copy `cardio:ctgov-nct06825182-2025-02-13`, retrieved 2026-10-26)
- Completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT06825182, source copy `cardio:ctgov-nct06825182-2025-02-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06825182, source copy `cardio:ctgov-nct06825182-2025-02-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06825182-2025-02-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Outpatient newly diagnosed type 2 diabetes subjects
- Intervention (Drug): Inpatient newly diagnosed type 2 diabetes subjects
- Lead sponsor: Nanjing First Hospital, Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Nanjing First Hospital, Nanjing Medical University (`cardio:org-nanjing-first-hospital-nanjing-medical-university`)

## Provenance

Content hash: 1d07eec7267595c4e5f8a0b4255c6530180df5c294997f057d6b08a01b6af4a4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
